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PAF is a potent in￿ ammatory compound known
to stimulate the release of various cytokines in-
volved in rheumatic diseases. Elevated blood PAF
levels are reported in these patients. We report
that serum PAF acetylhydrolase activity (AHA)
levels are decreased in patients with rheumatoid
arthritis or osteoarthritis as compared to healthy
controls. Serum and synovial ￿ uid AHA levels
were correlated in these patients. The present
study suggests the potential role of AHA in
controling systemic and/or local PAF levels in
patients with rheumatic diseases.
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Introduction
Platelet-activating factor (PAF), a phospholipid
molecule with potent in￿ammatory activities, is
involved in several in￿ammatory ailments in
man.1 Thus, regulating PAF levels is of impor-
tance since elevated concentrations of PAF
could result in pathological effects.1 Blood PAF
levels are regulated by an acetylhydrolase activ-
ity (AHA) found in plasma and serum.2 PAF is
present in blood and synovial ￿uid of patients
with various arthropathies with higher concen-
trations in rheumatoid arthritis.3 It is reported
that these patients have higher serum AHA
levels than healthy controls,4 a result that does
not ￿t well with their elevated blood PAF levels.
Contradictory results are also reported concern-
ing the correlation between AHA levels in
synovial ￿uid and serum of rheumatoid arthritis
patients.4,5 In order to clarify these points, we
have assessed AHA in the serum and synovial
￿uid of patients with rheumatoid arthritis and
osteoarthritis.
Patients and Methods
Samples were obtained from patients presenting
active disease and from healthy individuals ac-
cording to the Helsinki recommendations. Fifty
four patients had a rheumatoid arthritis accord-
ing to the American Rheumatism Association
criteria. The sex ratio (M/F) was 0.5 and the
average age was 61.2 years (range 27±75).
Twenty six patients had a symptomatic osteo-
arthritis; the sex ratio in this group was 1 and
the average age was 67.7 years (range 45±75).
Seventy four healthy individuals served as con-
trols; the sex ratio (M/F) was 2.2 and the
average age was 50.7 years (range 20±98). Sera
(collected from all patients and controls) and
synovial ￿uids (collected from 12 and 13 pa-
tients with rheumatoid arthritis and osteoarthri-
tis, respectively) were stored at - 808 C until
assay of AHA.
AHA was measured by the degradation of
[3H]PAF as previously reported.6,7 Brie￿y 1 3
105 dpm of 1-0-alkyl-2-[3H]acetyl-glycerophos-
phocholine ([3H]acetyl-PAF , 10 Ci/mmol, NEN),
0.1 mM PAF , HEPES buffer (pH 7.8) in a ￿nal
volume of 450 ml, and 50 ml diluted serum (1:50
dilution in HEPES buffer) were incubated for
20 min at 37 8 C. The reaction was stopped with
100 ml BSA (10% ) and 400 ml trichloracetic acid
(20% ). Samples were centrifuged (1500 3 g,
15 min) and supernatants counted in a liquid
scintillation counter. Results are expressed as
nanomoles PAF degraded per ml of serum or
synovial ￿uid (nmol/min/ml) as means of dupli-
cate determinations. The variation between
duplicates was less than 6% .
Differences between groups were assessed by
Mann±Whitney U-test. Serum and synovial ￿uid
AHA levels were correlated by linear regression
analysis.
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Serum AHA levels were signi￿cantly (P <
0·0004) decreased in patients with rheumatoid
arthritis (49·7 2·2 nmol/min/ml) or osteoar-
thritis (62·8 3·2 nmol/min/ml) as compared
to healthy controls (74·3 1·9 nmol/min/ml)
(Fig. 1). AHA levels in synovial ￿uid were not
signi￿cantly (P = 0·91) different in patients
with rheumatoid arthritis (41·8 5·5 nmol/
ml/min) and osteoarthritis (44·9 8·0 nmol/
ml/min). Serum and synovial ￿uid AHA levels
were correlated in patients with rheumatoid
arthritis (r = 0·83, P = 0·0016) and osteoarthri-
tis (r = 0·57, P = 0·04).
Serum AHA levels in our healthy individuals
were similar to previous reports by us and
others. 7- 11 As already documented,4,5 we found
that AHA levels in synovial ￿uid were not
different in patients with rheumatoid arthritis
and osteoarthritis. In our study, AHA levels in
synovial ￿uid were correlated with those in the
serum. In contrast to a previous report,4 we
found a signi￿cant decrease of serum AHA
levels in patients with rheumatic diseases espe-
cially in those with rheumatoid arthritis. This
result might, in part, explain the elevated cir-
culating blood PAF levels reported in these
patients.3 PAF is a potent in￿ammatory com-
pound known to stimulate the release of
various cytokines (such as IL-1, IL-6 and TNF-a)
involved in rheumatoid arthritis.12,13 Thus, the
present study suggests the potential role of AHA
in controlling systemic and/or local PAF levels
in patients with rheumatic diseases.
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FIG. 1. Serum AHA levels in patients with rheumatic dis-
eases and in healthy individuals. Results are expressed in
nmol/min/ml (individual data). Differences were assessed
by the Mann±Whitney U-test. The shaded areas represent
the mean SEM of values.
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